Health insurance: Incentivizing overspending or fueling innovation?

Based on a study by Frankovic and Kuhn (2022), the answer is both. However, the value of increased innovation–as measured through longevity gains–more than offset inefficiencies from overspending. Specifically, the authors use an overlapping generations model where individuals can purchase health insurance and medical progress depends on health care sector return on investment. The authors…

Challenge in HTA for gene therapies

Last month, the Office of Health Economics published a report titled “Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?” I summarize some of the key challenges and solutions below. Challenge #1: Initial assessment of clinical effectiveness. Since gene therapies often target rare disease, the sample size from clinical trials is often…

All stocks are vaccine stocks

In a world with COVID-19, what factors are most influential to a company’s stock price? Are company specific or macroeconomic factors most important? It turns out, the speed of health care innovation in fighting COVID-19 may be the biggest single factor influencing all stock market prices. Barrons: General Electric stock was racing higher Tuesday, but…